Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving hydrolase
Reexamination Certificate
1999-05-19
2001-07-03
Marschel, Ardin H. (Department: 1631)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving hydrolase
C435S021000, C435S025000, C435S026000, C436S071000
Reexamination Certificate
active
06255063
ABSTRACT:
1. FIELD OF THE INVENTION
The present invention relates to enzyme methods for detecting lysophospholipids, such as lysophosphatidic acid, (LysoPA) and lysophosphatidyl choline (LysoPC), in biological fluids, and for correlating and detecting conditions associated with altered levels of lysophospholipids.
2. BACKGROUND OF THE INVENTION
Phosphatidyl choline (PC), also named lecithin, is one of the major sources of polyunsaturated fatty acids such as arachidonic and linoleic acids. The former is a precursor of eicosanoids which have numerous biological activities. Hydrolysis of PC yields lysophosphatidyl choline (LysoPC) and constituent fatty acids, which have been implicated in signal transduction (Asaoka et al.,
Proc. Natl. Acad. Sci. USA
90:4917-4921 (1993); Yoshida et al.,
Proc. Natl. Acad. Sci. USA
89:6443-6446 (1992)). An increasing body of evidence indicates that LysoPC, which is present in high concentrations in oxidized low density lipoproteins may play a significant role in atherogenesis and other inflammatory disorders (Steinberg et al.,
New. Eng. J. Med
. 320:915-924 (1989)). LysoPC has been reported to increase the transcription of genes encoding platelet derived growth factor A and B chains, and heparin-binding epidermal growth factor-like protein (HB-EGF) in cultured endothelial cells (Kume and Gimbrone,
J. Clin. Invest
. 93:907-911 (1994)), and to increase mRNA encoding HB-EGF in human monocytes (Nakano et al.,
Proc. Natl. Acad. Sci. USA
91:1069-1073 (1994)). These gene products are mitogens for smooth muscle cells and fibroblasts (Higashiyama et al.,
Science
251:936-939 (1991); Ross,
Nature
(
Lond
.) 362:801-809 (1993)). LysoPC has also been shown to activate protein kinase C in vitro (Sasaki et al., FEBS Letter 320:47-51 (1993)), to potentiate the activation of human T lymphocytes (Asaoka et al.,
Proc. Natl. Acad. Sci. USA
89:6447-6451 (1992)) and to potentiate the differentiation of HL-60 cells to macrophages induced by either membranepermeable diacylglycerols or phorbol esters (Asaoka et al.,
Proc. Natl. Acad. Sci. USA
90:4917-4921 (1993)).
LysoPC may also provide a source of bioactive lysophosphatidic acid (1-acyl-sn-glycero-3-phosphate, LysoPA) (Moolenaar et al.,
Rev. Physiol. Biochem. Pharmacol
. 119:47-65 (1992)) through hydrolysis by lysophospholipase D (Tokumara et al.,
Biochim. Biophys. Acta
875:31-38 (1986)). LysoPA is a naturally occurring phospholipid with a wide range of growth factor-like biological activities. It is well established that LysoPA can act as a precursor of phospholipid biosynthesis in both eukaryotic and prokaryotic cells (Van den Bosch,
Ann. Rev. Biochem
. 43:243-277 (1974); Racenis et al.,
J. Bacteriol
. 174:5702-5710 (1992)). The ability of LysoPA to act as an intercellular lipid mediator has been noted (Vogt,
Arch. Pathol. Pharmakol
. 240:124-139 (1960); Xu et al.,
J. Cell. Phvsiol
. 163:441-450 (1995); Xu et al.,
Biochemistry
309:933-940 (1995); Tigyi et al.,
Cell Biol
. 91:1908-1912 (1994); Panetti et al.,
J. Lab. Clin. Med
. 129(2):208-216 (1997)). LysoPA is rapidly generated by activated platelets and can stimulate platelet aggregation and wound repair.
Ovarian cancer activating factor (OCAF), has been isolated from ovarian cancer ascites fluid (Mills et al.,
Cancer Res
. 48:1066 (1988); Mills et al.
J. Clin. Invest
. 86:851 (1990) and U.S. Pat. Nos. 5,326,690 and 5,277,917) and has been identified to consist of multiple forms of LysoPA (Xu et al.,
Clin. Cancer Res
. 1:1223-1232 (1995)). LysoPA has been identified as a potent tumor growth factor in the ascites fluid of ovarian cancer patients (Id.)
Other lysophospholipids associated with various conditions include lysophosphatidyl serine (LysoPS), lysophosphatidyl ethanolamine (LysoPE), lysophosphatidyl glycerol (LysoPG and lysophosphatidyl inositol (LysoPI). Activated platelets secrete two kinds of phospholipase: sPLA2 and PS-PLA1. sPLA2 is reported to be elevated in inflammatory reactions and inhibition of this enzyme reduced inflammation (Schrier et al.,
Arthritis Rheum
. 39(8):1292-1299 (1996); Tramposch et al.,
Pharmacol. and Experimental Therapeutics
271(2):852-859 (1994)). PS-PLA1 hydrolyzes phosphatidylserine or lysophosphatidyl serine (LysoPS) specifically to produce LysoPS or Glycerol-3-P serine. LysoPS strongly enhances degranulation of rat mast cells induced by concanavalin A and potentiates histamine release (Tamori-Natori et al.,
J. Biochem (Tokyo)
100(3):581-590 (1986)), and can stimulate sPLA2-elicited histamine release from rat serosal mast cells (Hara et al.,
Biol. Pharm. Bull
. 19(3):474-476 (1996)). LysoPS is an inflammatory lipid mediator (Lloret et al.,
J. Cell Physiol
. 165(1):89-95 (1995)) and sPLA2 has been implicated in inflammation processes (Lloret et al.,
Toxicon
32(11):1327-1336 (1994)). LysoPI has been shown to stimulate yeast adenylyl cyclase activity with implications for modulating the activity of downstream effector molecules and their interaction with RAS proteins (Resnick and Thomaska,
J. Biol. Chem
. 269(51):32336-32341 (1994)).
Methods for separating and semi-quantitatively measuring phospholipids such as LysoPA using techniques such as thin-layer chromatography (TLC) followed by gas chromatography (GC) and/or mass spectrometry (MS) are known. For example, lipids may be extracted from the test sample of bodily fluid using extraction procedures such as those described by Bligh and Dyer, Can.
J. Biochem. Physiol
. 37:911-917 (1959). Thin-layer chromatography may be used to separate various phospholipids, for example as described by Thomas and Holub,
Biochim. Biophys. Acta
, 1081:92-98 (1991). Phospholipids and lysophospholipids are then visualized on plates, for example using ultraviolet light as described by Gaudette et al.,
J. Biol. Chem
. 268:13773-13776 (1993). Alternatively, lysophospholipid concentrations can be identified by NMR or HPLC following isolation from phospholipids or as part of the phospholipid (Creer and Gross,
Lipids
20(12):922-928 (1985) and Bowes et al.,
J. Biol. Chem
. 268(19)13885-13892 (1993)). LysoPA levels have also been determined in ascites from ovarian cancer patients using an assay that relies on LysoPA-specific effects on eukaryotic cells in culture (Mills et al.,
Cancer Res
. 48:1066-1071 (1988)). However, these prior procedures are time-consuming, expensive and variable and typically only semi-quantitative.
Development of a rapid and sensitive assay for lysophospholipid species would facilitate use of these lysophospholipids as markers for cellular activities such as platelet activation and for conditions associated with altered levels of lysophospholipid species. Moreover, such assays would provide a method for determining correlations between altered levels of a lysophospholipid and conditions associated with such altered levels.
3. SUMMARY OF THE INVENTION
The present invention encompasses enzymatic methods for determining concentrations of lysophospholipids, such as LysoPA, in samples of biological fluids such as serum or plasma. The methods involves a two-step enzymatic digestion of at least one type of lysophospholipid to produce a substrate for a subsequent enzymatic reaction which produces a detectable end product that then permits detection of the concentration of the lysophospholipid.
The methods are carried out by detecting the concentration of a lysophospholipid such as LysoPA in a sample of bodily fluid taken from a subject. The lysophospholipid in the sample is preferably first enriched through extraction of lipids. For example, polar lipids are redissolved in aqueous solution and the concentration of lysophospholipid is determined using a two-step enzymatic reaction. The lysophospholipid is digested using an enzyme to generate a product that is then subject to a second enzymatic reaction. In a specific embodiment, the second reaction is an enzymatic cycling reaction that amplifies the signal. This method permits measurement of a lysophospholipid present in small amounts in the test sample.
In one embodiment, an enzyme such as lysophospholipase
Parrott Jeff A.
Small Christopher L.
Xu Liang Shong
Atairgin Technologies, Inc.
Lyon & Lyon LLLP
Marschel Ardin H.
Moran Marjorie A.
LandOfFree
Disease conditions by measuring lysophosphatidic acid does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Disease conditions by measuring lysophosphatidic acid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Disease conditions by measuring lysophosphatidic acid will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2451671